The integration of PD-1/PD-L1 inhibitors with antiangiogenic agents has demonstrated superior efficacy in multiple solid malignancies, especially the combination of pembrolizumab and lenvatinib has made a sustainable advancement in the management of advanced endometrial cancer. This evidence concerns the gene CD274 and endometrial cancer.